Genes and Fibrinolytic Capacity of Human Endothelium

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Nancy J. Brown, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00139503
First received: August 29, 2005
Last updated: December 18, 2012
Last verified: December 2012
  Purpose

To conduct several studies on genes and the fibrinolytic capacity of human endothelium.


Condition Intervention
Cardiovascular Diseases
Heart Diseases
Thrombosis
Blood Disease
Coronary Disease
Drug: angiotensin converting enzyme inhibitor

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Genes and Fibrinolytic Capacity of Human Endothelium

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Net t-LA release [ Time Frame: minutes ] [ Designated as safety issue: No ]
    Net t-PA release from the forearm vasculature


Enrollment: 48
Study Start Date: August 2000
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Effect of smoking on t-PA release Drug: angiotensin converting enzyme inhibitor

  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00139503

Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Nancy Brown Vanderbilt University
  More Information

Publications:

Responsible Party: Nancy J. Brown, Professor and Chair, Department of Medicine, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00139503     History of Changes
Other Study ID Numbers: 245, R01HL065193
Study First Received: August 29, 2005
Last Updated: December 18, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Disease
Coronary Artery Disease
Heart Diseases
Hematologic Diseases
Thrombosis
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Embolism and Thrombosis
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014